NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Thomas A. Hope; Lisa Bodei; Jennifer A. Chan; Ghassan El-Haddad; Nicholas Fidelman; Pamela L. Kunz; Josh Mailman; Yusuf Menda; David C. Metz; Erik S. Mittra; Daniel A. Pryma; Diane L. Reidy-Lagunes; Simron Singh; Jonathan R. Strosberg

doi:10.2967/jnumed.119.240911

Research ArticleTheranostics

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Thomas A. Hope, Lisa Bodei, Jennifer A. Chan, Ghassan El-Haddad, Nicholas Fidelman, Pamela L. Kunz, Josh Mailman, Yusuf Menda, David C. Metz, Erik S. Mittra, Daniel A. Pryma, Diane L. Reidy-Lagunes, Simron Singh and Jonathan R. Strosberg

Journal of Nuclear Medicine February 2020, 61 (2) 222-227; DOI: https://doi.org/10.2967/jnumed.119.240911

Thomas A. Hope

1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California

2Department of Radiology, San Francisco VA Medical Center, San Francisco, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lisa Bodei

3Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jennifer A. Chan

4Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ghassan El-Haddad

5Department of Radiology, Moffitt Cancer Center, Tampa, Florida

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nicholas Fidelman

1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Pamela L. Kunz

6Department of Medicine, Stanford University School of Medicine, Stanford, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Josh Mailman

7NorCal CarciNET Community, Ripon, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yusuf Menda

8Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David C. Metz

9Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Erik S. Mittra

10Department of Diagnostic Radiology, Division of Nuclear Medicine & Molecular Imaging, Oregon Health & Science University, Portland, Oregon

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Daniel A. Pryma

11Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Diane L. Reidy-Lagunes

12Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Simron Singh

13Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jonathan R. Strosberg

14Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 61 no. 2 222-227

DOI

https://doi.org/10.2967/jnumed.119.240911

PubMed

32015164

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Received for publication December 12, 2019
Accepted for publication December 12, 2019
Published online February 3, 2020.

Author Information

Statistics from Altmetric.com

Cited By...

87 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

Anna Sundlöv, Katarina Sjögreen Gleisner, Jan Tennvall, Michael Ljungberg, Carl Fredrik Warfvinge, Kajsa Holgersson, Andreas Hallqvist, Peter Bernhardt, Johanna Svensson

European Journal of Nuclear Medicine and Molecular Imaging 2022 49 11
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors

Sara Pusceddu, Natalie Prinzi, Salvatore Tafuto, Toni Ibrahim, Angelina Filice, Maria Pia Brizzi, Francesco Panzuto, Sergio Baldari, Chiara M. Grana, Davide Campana, Maria Vittoria Davì, Dario Giuffrida, Maria Chiara Zatelli, Stefano Partelli, Paola Razzore, Riccardo Marconcini, Sara Massironi, Fabio Gelsomino, Antongiulio Faggiano, Elisa Giannetta, Emilio Bajetta, Franco Grimaldi, Mauro Cives, Fernando Cirillo, Vittorio Perfetti, Francesca Corti, Claudio Ricci, Luca Giacomelli, Luca Porcu, Massimo Di Maio, Ettore Seregni, Marco Maccauro, Secondo Lastoria, Alberto Bongiovanni, Annibale Versari, Irene Persano, Maria Rinzivillo, Salvatore Antonio Pignata, Paola Anna Rocca, Giuseppe Lamberti, Sara Cingarlini, Ivana Puliafito, Maria Rosaria Ambrosio, Isabella Zanata, Alessandra Bracigliano, Stefano Severi, Francesca Spada, Valentina Andreasi, Roberta Modica, Federica Scalorbi, Massimo Milione, Giovanna Sabella, Jorgelina Coppa, Riccardo Casadei, Maria Di Bartolomeo, Massimo Falconi, Filippo de Braud

JAMA Network Open 2022 5 2
How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy

Brian J. Burkett, Ayca Dundar, Jason R. Young, Annie T. Packard, Geoffrey B. Johnson, Thorvardur R. Halfdanarson, Rachel A. Eiring, Denise N. Gansen, Cynthia M. Patton, A. Tuba Kendi

Radiology 2021 298 2
Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma

Andrew L Lin, Viviane Tabar, Robert J Young, Marc Cohen, John Cuaron, T Jonathan Yang, Marc Rosenblum, Vasilisa A Rudneva, Eliza B Geer, Lisa Bodei

Journal of the Endocrine Society 2021 5 10
Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

Thomas A. Hope, Marianne Pavel, Emily K. Bergsland

Journal of Clinical Oncology 2022 40 24
Peptide Receptor Radionuclide Therapy

Johannes Hofland, Tessa Brabander, Frederik A Verburg, Richard A Feelders, Wouter W de Herder

The Journal of Clinical Endocrinology & Metabolism 2022 107 12
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

Valentina Ambrosini, Lucia Zanoni, Angelina Filice, Giuseppe Lamberti, Giulia Argalia, Emilia Fortunati, Davide Campana, Annibale Versari, Stefano Fanti

Cancers 2022 14 4
Targeted radionuclide therapy: an emerging field in solid tumours

Carlos Artigas, Magdalena Mileva, Patrick Flamen, Ioannis Karfis

Current Opinion in Oncology 2021 33 5
Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells

Rashmi G. Shah, Marine A. Merlin, Samuel Adant, Fayçal Zine-Eddine, Jean-Mathieu Beauregard, Girish M. Shah

Cancers 2021 13 2
Small Bowel Neuroendocrine Tumors

Catherine G. Tran, Scott K. Sherman, James R. Howe

Current Problems in Surgery 2020 57 12

Article usage

Article usage: February 2020 to March 2025

	Abstract	Full	Pdf
Feb 2020	121	205	214
Mar 2020	34	34	41
Apr 2020	27	20	25
May 2020	29	28	29
Jun 2020	19	20	21
Jul 2020	10	12	8
Aug 2020	16	55	36
Sep 2020	0	83	39
Oct 2020	0	79	38
Nov 2020	0	82	33
Dec 2020	0	74	31
Jan 2021	0	92	52
Feb 2021	0	77	51
Mar 2021	0	80	44
Apr 2021	0	95	56
May 2021	0	72	111
Jun 2021	0	86	52
Jul 2021	0	81	42
Aug 2021	0	65	40
Sep 2021	0	92	46
Oct 2021	0	89	75
Nov 2021	0	81	62
Dec 2021	0	81	26
Jan 2022	0	101	40
Feb 2022	0	81	29
Mar 2022	0	85	38
Apr 2022	0	116	42
May 2022	0	74	33
Jun 2022	0	86	45
Jul 2022	0	74	50
Aug 2022	0	65	32
Sep 2022	0	65	32
Oct 2022	0	48	23
Nov 2022	0	58	28
Dec 2022	0	65	26
Jan 2023	0	95	35
Feb 2023	0	61	25
Mar 2023	0	84	27
Apr 2023	0	70	25
May 2023	0	59	25
Jun 2023	0	69	25
Jul 2023	0	68	31
Aug 2023	0	71	34
Sep 2023	0	82	35
Oct 2023	0	102	43
Nov 2023	0	89	29
Dec 2023	0	92	20
Jan 2024	0	114	30
Feb 2024	0	157	32
Mar 2024	0	108	54
Apr 2024	0	239	34
May 2024	0	145	30
Jun 2024	0	114	30
Jul 2024	0	140	46
Aug 2024	0	165	37
Sep 2024	0	135	32
Oct 2024	0	133	42
Nov 2024	0	135	34
Dec 2024	0	118	32
Jan 2025	0	97	22
Feb 2025	0	169	26
Mar 2025	0	175	55

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 61, Issue 2

February 1, 2020

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine Feb 2020, 61 (2) 222-227; DOI: 10.2967/jnumed.119.240911

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine Feb 2020, 61 (2) 222-227; DOI: 10.2967/jnumed.119.240911

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy
Safety and Efficacy of Para-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors
Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin {alpha}v{beta}3 for Prognostication in Patients with Neuroendocrine Neoplasms
A 2022 International Survey on the Status of Prostate Cancer Theranostics
Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright

Google Scholar

Theranostics

¹⁷⁷Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Terbium-161, a Promising New Theranostic Radionuclide
Association of change in PSMA avid tumor burden during 177Lu-PSMA-617 therapy with overall survival: Should mid-point PET become standard protocol?

Show more Theranostics

Clinical

Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
Tau^IQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans

Show more Clinical

Main menu

User menu

Search

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Article Information

Author Information

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: February 2020 to March 2025

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Theranostics

Clinical

Similar Articles